Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.
Sino Biopharmaceutical Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results for the financial year ended 31 December 2025. At the same meeting, the board will also consider whether to recommend a final dividend, a decision that could affect shareholder returns and signal management’s view of the company’s recent performance.
The announcement formalizes the timetable for the release of the 2025 financial report, providing investors with clarity on when key performance information will be disclosed. The consideration of a potential final dividend underscores the company’s ongoing capital allocation policy and may influence market expectations regarding its profitability and cash flow strength.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical company incorporated in the Cayman Islands, focusing on the research, development, production, and sale of biopharmaceutical and related healthcare products. The company is governed by a board comprising six executive directors and five independent non-executive directors, reflecting a conventional governance structure for a major regional drug manufacturer.
YTD Price Performance: -3.72%
Average Trading Volume: 65,270,677
Technical Sentiment Signal: Buy
Current Market Cap: HK$106.4B
For detailed information about 1177 stock, go to TipRanks’ Stock Analysis page.